Dr. Nanus Discusses Immunotherapy in Kidney Cancer

David M. Nanus, MD
Published: Thursday, Apr 05, 2018



David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of immunotherapy in the treatment of patients with kidney cancer.

Immunotherapy is a promising therapy for patients with kidney cancer, says Nanus. There are preliminary results from many studies that show exciting results. The use of immunotherapy has a lot of rationale and is generating a lot of excitement, Nanus adds. However, there are questions as to when would be the best time to use immunotherapy. The concept of giving some immunotherapy first so immune system can recognize the tumor, then remove the tumor surgically, and then continuing immunotherapy appears to be an effective strategy.

There is a large trial using 2 cycles of nivolumab (Opdivo), followed by surgery and then the patient is given more nivolumab. Throughout multiple cancer types, there seems to be a role for immunotherapy for high-risk, relapsed patients, especially since the toxicity profile is good, Nanus explains. There will be combination studies of immunotherapy with tyrosine kinase inhibitors. Overall, there is a lot of hope and optimism that immunotherapy is going to improve the outcome of these patients.
 
SELECTED
LANGUAGE


David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of immunotherapy in the treatment of patients with kidney cancer.

Immunotherapy is a promising therapy for patients with kidney cancer, says Nanus. There are preliminary results from many studies that show exciting results. The use of immunotherapy has a lot of rationale and is generating a lot of excitement, Nanus adds. However, there are questions as to when would be the best time to use immunotherapy. The concept of giving some immunotherapy first so immune system can recognize the tumor, then remove the tumor surgically, and then continuing immunotherapy appears to be an effective strategy.

There is a large trial using 2 cycles of nivolumab (Opdivo), followed by surgery and then the patient is given more nivolumab. Throughout multiple cancer types, there seems to be a role for immunotherapy for high-risk, relapsed patients, especially since the toxicity profile is good, Nanus explains. There will be combination studies of immunotherapy with tyrosine kinase inhibitors. Overall, there is a lot of hope and optimism that immunotherapy is going to improve the outcome of these patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x